Wintermute Biomedical services

Antimicrobial Resistance (AMR) is among the greatest global health challenges of our time. AMR occurs when a micro-organism becomes resistant to an antimicrobial medicine, such as an antibiotic. Today, an estimated 700,000 people die each year from drug-resistant infections. More alarmingly, this number is projected to accelerate towards 10 million by 2050, outstripping even cancer (Review on Antimicrobial Resistance, UK Government, 2014).

Wintermute launched the Doxall™ Sanitiser range in 2021 and has multiple other therapeutic formulations in its development pipeline. These including a Covid 19 preventative and treatment inhalant and a topical shingles therapeutic. Wintermute formulations demonstrate exceptional potential for the treatment of infections. Some key advantages of include.